The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Durie et al., N Engl J Med 353(1):99-102 July 7, 2005.

Correction
PreviousPrevious
Volume 353:2728 December 22, 2005 Number 25

Osteonecrosis of the Jaw and Bisphosphonates

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Durie, B. G.M.
Osteonecrosis of the Jaw and Bisphosphonates . On page 101, lines 5 through 8 of the letter by Tarassoff and Hei should have read, "As the developer of Aredia (pamidronate) and Zometa (zoledronic acid), we have implemented labeling revisions for these two drugs with the approval of the Food and Drug Administration and based on best clinical judgment," rather than ". . . we have obtained expert advice on how to revise the labels for these two drugs," as printed.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.